Inhibikase Therapeutics (NYSE:IKT) versus Big Cypress Acquisition (OTCMKTS:BCYP) Head to Head Analysis

Big Cypress Acquisition (OTCMKTS:BCYP) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Valuation and Earnings

This table compares Big Cypress Acquisition and Inhibikase Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Big Cypress Acquisition	N/A	N/A	-$10,000.00	N/A	N/A
Inhibikase Therapeutics	N/A	N/A	-$19.03 million	($0.39)	-4.51

Profitability

This table compares Big Cypress Acquisition and Inhibikase Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Big Cypress Acquisition	N/A	N/A	N/A
Inhibikase Therapeutics	N/A	-350.63%	-201.82%

Insider and Institutional Ownership

60.2% of Big Cypress Acquisition shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 7.3% of Inhibikase Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for Big Cypress Acquisition and Inhibikase Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Big Cypress Acquisition	0	0	0	0	0.00
Inhibikase Therapeutics	0	0	4	0	3.00

Inhibikase Therapeutics has a consensus price target of $6.00, indicating a potential upside of 240.91%. Given Inhibikase Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Big Cypress Acquisition.

About Big Cypress Acquisition

Big Cypress Acquisition Corp. does not have significant operations. The company intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It primarily focuses in the life science sector. The company was incorporated in 2020 and is based in Miami Beach, Florida.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.